Previous 10 | Next 10 |
2023-11-28 10:52:22 ET The U.S. Food and Drug Administration (FDA) on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies directed towards the proteins BCMA and CD19. The regulator said it had determined that ...
NORTHAMPTON, MA / ACCESSWIRE / November 28, 2023 / "At Gilead, we have a bold ambition: We'd like to help end the HIV epidemic for everyone, everywhere and we know you cannot do that alone," shared Janet Dorling, Senior Vice President, Intercontinental Region and Global Patient Solutions. Throu...
2023-11-26 06:55:00 ET Are you a pro when it comes to procrastination? Some investors take so long to make a decision on buying stocks that they miss out on great upside moves. And when those stocks pay juicy dividends, they also miss out on income. Three Motley Fool contributors think ...
2023-11-22 07:17:09 ET More on the markets SPY: Sell The Rally - Historical Patterns Show Misplaced Optimism S&P 500: Forget The Year-End Rally The Message From 12 Post-CPI Charts Chart Talk: S&P 500 hasn’t hit an all-time high in 471 days, sev...
2023-11-22 06:42:30 ET Summary Under Armour has struggled for the better part of a year. However, it shows signs of bottoming, due to a better technical and fundamental picture. Fundamentals in particular make the stock a compelling buy. The company is very cheap on a PEG ...
2023-11-21 10:30:55 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) soared 6.7% amid takeover speculation. The Aurinia ( AUPH ) stock surge comes amid a report that a Gilead Sciences ( GILD ) corporate jet made a trip to Aurinia's headquarters in Edmonton, Canada, accord...
NORTHAMPTON, MA / ACCESSWIRE / November 21, 2023 / Gilead Sciences Claudia Hardy says she's found her life's mission. As director of Community Health Access and Relations for the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham - the only National Cancer Institute-D...
2023-11-19 12:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Perfectly Priced Healthcare Giant Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event (Transcript) Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise ...
2023-11-15 15:37:21 ET Summary Gilead Sciences has a robust pipeline in oncology and HIV, indicating sustained growth potential. The company offers dividends, buybacks, and an attractive valuation, making it an appealing investment option. Gilead's path to $100 per share is pl...
2023-11-15 13:44:49 ET Summary Arcellx's CART-ddBCMA reported strong and competitive data in late-line multiple myeloma patients, positioning it well against CAR-T leader Carvykti. The updated data at ASH show that the efficacy held up and even slightly improved compared to the pr...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...